Результаты поиска

Case Report: Ofatumumab pourpura - лечение в связи с сопутствующим множественным склерозом и идиопатическим тромбоцитопентом.

В этой связи мы подробно рассказываем о нашем опыте с уникальным пациентом с сопутствующим множественным склерозом (MS) и идиопатическим тромбоцитопеническим пурпурным (ИТП) лечением от атумумаба, что привело к стабильной активности заболеваний и нормализации количества тромбоцитов. ПРЕДСТАВЛЕНИЕ СЛУЧАИ: А 21-year-old Японская женщина имела средний продольный синдром фаскилуса и впоследствии получила диагноз MS. Её лечили метилпреднизолоном (Пульсовая терапия).1,000 мг/сут. 5 днями). Во время ее первой госпитализации количество тромбоцитов было низким.40 × 109/L). На основе исследований, серол

Совпадение в аннотации оригинала
BACKGROUND: Herein, we detail our experience with a unique patient with concomitant multiple sclerosis (MS) and idiopathic thrombocytopenic … rednisolone pulse and DMD adjustments (the DMT was sequentially switched from glatiramer acetate to dimethyl fumarate, then fingolimod, and finally natalizumab). Despite an initial recovery of the platelet count following these interventions, the platelet count declined correspondingly with the prednisolone dose reduction. Finally, the DMD was switched to ofatumuma …

Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination.

INTRODUCTION: Disease-modifying therapies (DMTs) have been shown to improve disease outcomes in multiple sclerosis (MS) patients. They may also impair the immune response to vaccines, including the SARS-CoV-2 vaccine. However, available data on both the intrinsic immune effects of DMTs and their influence on cellular response to the SARS-CoV-2 vaccine are still incomplete. METHODS: Here, we evaluated the immune cell effects of 3 DMTs on the response to mRNA SARS-CoV-2 vaccination by comparing MS patients treated with one specific therapy (fingolimod, dimethyl fumarate, or natalizumab) with bo…

A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

BACKGROUND: Most people with Multiple Sclerosis (pwMS) are subjected to immunomodulatory disease-modifying treatments (DMTs). As a result, immune responses to COVID-19 vaccinations could be compromised. There are few data on cellular immune responses to the use of COVID-19 vaccine boosters in pwMS under a broad spectrum of DMTs. METHODS: In this prospective study, we analysed cellular immune responses to SARS-CoV-2 mRNA booster vaccinations in 159 pwMS with DMT, including: ocrelizumab, rituximab, fingolimod, alemtuzumab, dimethyl fumarate, glatiramer acetate, teriflunomide, natalizumab and cl…

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies.

BACKGROUND: Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic infection caused by John Cunningham virus (JCV) reactivation, potentially associated with natalizumab (NTZ) treatment for Multiple Sclerosis (MS). The anti-JCV antibodies titre (JCV index) increases during NTZ treatment; however, the effects of other disease-modifying therapies (DMTs) on the JCV index have not been fully explored. OBJECTIVE: The aim of the study was to evaluate changes in the JCV index during treatment with several DMTs. METHODS: This longitudinal study evaluated the JCV index before starting DM

Simultaneous Modulation of NLRP3 Inflammasome and Nrf2/ARE Pathway Rescues Thioacetamide-Induced Hepatic Damage in Mice: Role of Oxidative Stress and Inflammation.

Chronic tissue injury resulting in fibrosis of multiple organs, responsible for one-third of the death globally. Liver fibrosis is a common pathway/condition involved in all chronic liver diseases. Thioacetamide (TAA), a hepatotoxicant, was used to induce hepatic fibrosis. Anti-diabetic drug glibenclamide (GLB) possesses anti-inflammatory properties and inhibits NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome activation. Dimethyl fumarate (DMF), a multiple sclerosis drug, activates the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) p…

Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Several disease-modifying therapies have been show … utoimmunity after exposure to alemtuzumab, lymphocyte count with regard to PML risk while receiving dimethyl fumarate or N-terminal-pro-B-type natriuretic peptide (NT-proBNP) for monitoring of cardiac side effects during mitoxantrone therapy.

Sulforaphane Ameliorates 3-Nitropropionic Acid-Induced Striatal Toxicity by Activating the Keap1-Nrf2-ARE Pathway and Inhibiting the MAPKs and NF-κB Pathways.

The potential neuroprotective value of sulforaphane (SFN) in Huntington's disease (HD) has not been established yet. We investigated whether … F-κB) pathways in the striatum after 3-NP treatment. As expected, the pretreatment with activators (dimethyl fumarate and antioxidant response element inducer-3) of the Keap1-Nrf2-ARE pathway decreased the neurological impairment and lethality after 3-NP treatment. Our findings suggest that SFN may effectively attenuate 3-NP-induced striatal toxicity by activating …

Persistent expression of mitogenic/transforming factors at the site of failed orthopaedic implants: the impact on immune reactivity.

RATIONALE: The FDA-approved Dimethyl Fumarate (DMF) as an oral drug for Multiple Sclerosis (MS) treatment based on its immunomodulatory activities. However, it also caused severe adverse effects mainly related to the gastrointestinal system. OBJECTIVE: Investigated the potential effects of solid lipid nanoparticles (SLNs) containing DMF, administered by inhalation on the clinical signs, central nervous system (CNS) inflammatory response, and lung function changes in mice with experimental autoimmune encephalomyelitis (EAE). MATERIALS AND METHODS: EAE was induced using MOG35-55 peptide in fem…

:: проведение профилактических исследований, ориентированных на продромальную или предклиническую стадию иммуномедицинских заболеваний в интересах пациентов: обзор аналитического исследования.

ВАЖНЕЙШЕЕ: Немногие заболевания, включая множественный склероз (MS), ревматоидный артрит (RA), системный волшебный эритематос (SLE) и тип 1 До возникновения классического симптома диабет (T1D) часто проходит через продромальную или предклиническую фазу. Эти первые этапы открывают возможности для принятия превентивных мер, однако данные об их эффективности и безопасности систематически не обобщаются. ЦЕЛЬ: В рамках этого аналитического обзора была проведена оценка практических исследований, ориентированных на продромальные/доклинические этапы MS, RA, SLE и T1D с уделением особого внимания эффек

Совпадение в аннотации оригинала
BACKGROUND: Immune-mediated diseases, including multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and … 1D (adjusted HR = 0.41; 95% CI 0.22-0.78). For MS, teriflunomide (aHR = 0.28; 95% CI 0.11-0.71) and dimethyl fumarate (aHR = 0.07; 95% CI 0.01-0.45) lowered risk of clinical conversion in persons with radiologically isolated syndrome. Interventions demonstrated expected safety profiles. CONCLUSION: Interventions targeting preclinical or prodromal phases of immune- …

Sulforaphane Targets Multiple Pathological Processes in Friedreich Ataxia Patient-Induced Pluripotent Stem Cell-Derived Sensory Neurons.

Aims: In Friedreich ataxia (FRDA), early motor discoordination stems from dysfunctional sensory neurons in the spinal cord driven by epigenetic dysregulation, frataxin (FXN) deficiency, oxidative stress, and inflammation. Omaveloxolone, a nuclear factor erythroid 2-related factor-2 (NRF2) inducer, is the only treatment available. In various chronic disease models, sulforaphane (SF) can target NRF2 and the above processes. This study compared the effects of SF with omaveloxolone and dimethyl fumarate (DMF) in sensory neurons generated from FRDA patient-induced pluripotent stem cells and their i…

Распространение гипогаммаглобулинемии после лечения без антиCD20 и воздействие перехода на ритуксимаб/окрелизумаб при множественном склерозе.

Некоторые люди с множественным склерозом (PwMS) демонстрируют снижение уровня сыворотки иммуноглобулина (Ig), что может быть связано с модифицирующей болезни терапией (DMT), что вызывает обеспокоенность в связи с началом лечения против CD20. Мы провели оценку частоты гипогаммаглобулинемии в PwMS, которая ранее получала неантиCD20 DMT и оценивала краткосрочные изменения уровня Ig после перехода на rituximab (RTX) или ocrelizumab (OCR). Это ретроспективное исследование включало PwMS, начинающиеся с RTX или OCR с предварительного воздействия DMT или без него. Пациенты были сгруппированы по катего

Совпадение в аннотации оригинала
Some people with multiple sclerosis (PwMS) exhibit reduced serum immunoglobulin (Ig) levels, potentially due to disease-modifying therapies … g fingolimod (FING), natalizumab (NTZ), or moderate-efficacy DMTs (interferons, glatiramer acetate, dimethyl fumarate, or teriflunomide) before the switch. Among 417 included patients, 89 were treatment-naïve, 207 had received FING, 70 NTZ, and 51 moderate-efficacy DMTs. Before switching, hypogammaglobulinemia (IgG level <7 ​g/L) was rare in treatment-naïve and mod …

Disease modifying treatment of radiologically isolated syndrome: A systematic review of the use, efficacy, effectiveness, and safety.

BACKGROUND: Radiologically isolated syndrome (RIS) is characterized by incidental brain lesions suggestive of demyelination without symptoms … ere included; 291 (21%) received a DMT. The two RCTs randomized people with RIS to teriflunomide or dimethyl fumarate versus placebo and followed patients for at least 96weeks. In all other studies, follow-up ranged from 2months to 18years; only 3 studies exceeded 5years. DMT treatment was associated with a lower risk of a clinical demyelinating event (4 studies wi …

Риск инсульта при заболеваниях, изменяющий методы лечения множественных склерозов: систематический обзор.

Эпидемиологические исследования свидетельствуют об увеличении числа случаев цереброваскулярных расстройств у пациентов с множественным склерозом (МС). ЦЕЛИ: Цель настоящего систематического обзора состояла в том, чтобы изучить потенциальную связь между лечением, изменяющим заболевания (ДМТ), и риском инсульта в популяциях пациентов, страдающих НР. ИСТОЧНИКИ ДАННЫХ И МЕТОДЫ: В период до апреля в базах данных MedLINE и SCOPUS проводился систематический поиск литературы 6, 2024, для выявления случайных контролируемых клинических испытаний (РКТ), исследований на основе реестров и когортных исследо

Совпадение в аннотации оригинала
BACKGROUND: Epidemiological research indicates a heightened incidence of cerebrovascular disorders among patients with multiple sclerosis (M … a 50% reduction of the risk of stroke compared to no DMT exposure. Although glatiramer acetate and dimethyl fumarate appear to lower the risk of stroke, concerns about fingolimod exists due to an observed elevated risk for ischemic heart disease and hypertension. Despite the absence of detected safety concerns with alemtuzumab at the MS population level, alemtuzum …

Nrf2/HO-1 signaling activation alleviates cigarette smoke-induced inflammation in chronic obstructive pulmonary disease by suppressing NLRP3-mediated pyroptosis.

BACKGROUND: This study examined the effect of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway on chronic obstructive pulmonary disease (COPD) and the potential molecular mechanism. METHODS: A COPD mouse model was established by cigarette smoke exposure and administered with either ML385 or dimethyl fumarate (DMF). Airway resistance of mice was detected. IL-1β and IL-6 levels in mice alveolar lavage fluid were examined by enzyme-linked immunosorbent assay. Hematoxylin and eosin staining and immunohistochemical of lung tissues were utilized to detect lung …

Delayed initiation of disease modifying therapy increases relapse frequency and motor disability in pediatric onset multiple sclerosis.

OBJECTIVE: To evaluate association between time to initiation of disease modifying treatment (DMT) and outcomes in pediatric-onset Multiple … %), brainstem (23.5 %), and pyramidal (19.1 %) symptoms were most common. Interferon beta (32.4 %), dimethyl fumarate (27.9 %) and rituximab (26.5 %) were the most frequently used first-line DMT. Patients had a median ARR of 0.5 (IQR: 0.08-0.84), and EDSS score of 1.0 (IQR: 0.0-2.0) at the most recent follow-up. Delayed DMT initiation correlated with higher ARR (R …

Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.

INTRODUCTION: There are no reports in LATAM related to longitudinal humoral and cellular response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) under different disease modifying therapies (DMTs) and neutralization of the Omicron and Wuhan variants of SARS-COV-2. METHODS: IgG anti- SARS-COV-2 spike titer were measured in a cohort of 101 pwMS under fingolimod, dimethyl fumarate, cladribine and antiCD20, as well as 28 healthy controls (HC) were measured 6 weeks after vaccination with 2nd dose (Sputnik V or AZD1222) and 3nd dose (homologous or heterologous schedul…

Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.

BackgroundNon-Hispanic Black and Hispanic persons with MS (pwMS) are more likely to experience rapid disease progression and severe disabili … . The mean time from diagnosis to DMT initiation was 4.9 months in all pwMS. Glatiramer acetate and dimethyl fumarate were the most common first-line DMTs in non-Hispanic Black (28% and 20% respectively) and Hispanic pwMS (31%, 29%); however, glatiramer acetate and ocrelizumab were the most common in non-Hispanic White pwMS (33%, 18%). Use of first-line high-effica …

Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS.

OBJECTIVE: To investigate the association between disease-modifying therapies (DMTs) and the rate of progressive retinal ganglion cell (RGC) … ron-β and glatiramer acetate) compared with DMTs of higher clinical efficacy (including fingolimod, dimethyl fumarate, natalizumab, alemtuzumab, rituximab, and ocrelizumab) (difference = -0.22 μm/y, p = 0.02 for pRNFL; difference = -0.34 μm/y, p = 0.009 for tRNFL; and difference = -0.16 μm/y, p = 0.005 for GCIPL). Based on an analysis of individual treatments (inte …

Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.

Patients with multiple sclerosis on long-term injectable therapies may suffer from the so-called "needle fatigue", i.e., a waning commitment to continue with the prescribed injectable treatment. Therefore, alternative treatment strategies to enhance patients' adherence are warranted. In this independent, multicentre post-marketing study, we sought to directly compare switching to either teriflunomide (TFN), dimethyl fumarate (DMF), or pegylated interferon (PEG) on treatment persistence and time to first relapse over a 12-month follow-up. We analyzed a total of 621 patients who were free of rel…

Real-World Comparison of High-Efficacy Versus Non-High-Efficacy Therapies in Multiple Sclerosis.

OBJECTIVE: The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether hi … al-world, single-centre, longitudinal cohorts: (1) Relapsing-remitting MS (RRMS) patients initiated dimethyl fumarate, fingolimod, glatiramer acetate and natalizumab between 2002 and 2020; (2) RRMS patients initiated ocrelizumab between 2019 and 2021. We selected treatment-naïve patients and had at least 2 years of follow-up. We compared the two groups at years 1 a …